Kyverna Therapeutics, Inc. (KYTX) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.54
↑+32% vs avg
5yr avg: 1.16
30Y Low0.5·High1.8
ROE
↑
-64.7%
↓+98% vs avg
5yr avg: -3483.1%
30Y Low-126%·High-65%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KYTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Kyverna Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $353M | $416M | $143M | — | — | — |
| Enterprise Value | $258M | $321M | $55M | — | — | — |
| P/E Ratio → | -2.22 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 1.54 | 1.79 | 0.54 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KYTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
KYTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -64.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | -418.3% | -465.8% |
| Net Profit Margin | — | — | — | — | -411.3% | -465.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -64.7% | -64.7% | -80.7% | -126.0% | -13661.0% | — |
| ROA | -53.9% | -53.9% | -67.1% | -85.0% | -37.9% | -30.8% |
| ROIC | -80.8% | -80.8% | -106.0% | -217.1% | — | — |
| ROCE | -64.3% | -64.3% | -87.4% | -113.2% | -47.2% | -37.9% |
KYTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $124M exceeds total debt of $29M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.03 | 0.18 | 0.23 | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.41 | -0.33 | -0.52 | -0.58 | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -328.87 | -328.87 | -896.73 | -321.81 | -443.51 | -8782.33 |
Net cash position: cash ($124M) exceeds total debt ($29M)
KYTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Kyverna Therapeutics, Inc.'s current ratio of 7.75x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.05x to 7.75x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 7.75 | 7.75 | 8.61 | 3.05 | 4.45 | 4.84 |
| Quick Ratio | 7.75 | 7.75 | 8.61 | 3.05 | 4.45 | 4.84 |
| Cash Ratio | 7.65 | 7.65 | 8.47 | 2.90 | 4.29 | 4.78 |
| Asset Turnover | — | — | — | — | 0.10 | 0.07 |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
KYTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Kyverna Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $44M | $38M | $674M | $26M | $26M |
Peer Comparison
Compare KYTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KYTXYou | $353M | -2.2 | — | — | — | — | -64.7% | -80.8% | — |
 CABA | $463M | -1.7 | — | — | — | — | -127.0% | -429.6% | — |
 AUTL | $402M | -1.4 | — | — | -27.8% | -372.4% | -95.2% | -62.3% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 LEGN | $5B | -17.5 | — | — | 60.3% | -13.3% | -29.1% | -12.7% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 ALLO | $488M | -2.3 | — | — | — | — | -53.4% | -41.2% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
KYTX — Frequently Asked Questions
Quick answers to the most common questions about buying KYTX stock.
What is Kyverna Therapeutics, Inc.'s P/E ratio?
Kyverna Therapeutics, Inc.'s current P/E ratio is -2.2x. This places it at the 50th percentile of its historical range.
What is Kyverna Therapeutics, Inc.'s ROE?
Kyverna Therapeutics, Inc.'s return on equity (ROE) is -64.7%. The historical average is -90.5%.
Is KYTX stock overvalued?
Based on historical data, Kyverna Therapeutics, Inc. is trading at a P/E of -2.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.